Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioids: FDA Actions May Silence Call For Moratorium On Approvals

Executive Summary

Citizen petition seeks review of all marketed opioids; agency is considering whether new opioids should have comparative benefit over existing drugs.

Advertisement

Related Content

Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says
Opioid Sponsors Enter 2019 At A Crossroads
Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote
Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
New Opioids: FDA Should Ditch 'Product-Specific Approach,' Science Report Says
Opana ER Should Come Off The US Market, FDA Tells Endo
Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel